Natalizumab Affects T-Cell Phenotype in Multiple Sclerosis: Implications for JCV Reactivation

The anti-CD49d monoclonal antibody natalizumab is currently an effective therapy against the relapsing-remitting form of multiple sclerosis (RRMS). Natalizumab therapeutic efficacy is limited by the reactivation of the John Cunningham polyomavirus (JCV) and development of progressive multifocal leuk...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:PLoS One
Main Authors: Iannetta, Marco, Zingaropoli, Maria Antonella, Bellizzi, Anna, Morreale, Manuela, Pontecorvo, Simona, D’Abramo, Alessandra, Oliva, Alessandra, Anzivino, Elena, Lo Menzo, Sara, D’Agostino, Claudia, Mastroianni, Claudio Maria, Millefiorini, Enrico, Pietropaolo, Valeria, Francia, Ada, Vullo, Vincenzo, Ciardi, Maria Rosa
Formato: Artigo
Idioma:Inglês
Publicado em: Public Library of Science 2016
Assuntos:
Research Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4972347/
https://ncbi.nlm.nih.gov/pubmed/27486658
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1371/journal.pone.0160277
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados